Kabeer co-founded Adjuvant Capital after three years with the Global Health Investment Fund (GHIF). While at GHIF he was responsible for sourcing and analyzing new opportunities, including co-leading the fund’s investments in Univercells, Access Bio, and Atomo Diagnostics. Currently, at Adjuvant Capital, he has led and managed investments in AN2 Therapeutics (Board Member) and Themis Bioscience (Board Observer).
Prior to GHIF, Kabeer was an investment professional at Metalmark Capital, a private equity fund in New York, where he focused primarily on medical device investments. Kabeer also spent time at Greenhill & Co., a boutique investment bank, where he advised on M&A transactions in the biopharmaceutical and medical technology sectors. He graduated with honors from the Stern School of Business at New York University with a BS in Finance & Economics.